

# **Wockhardt Hospitals Limited**

December 21, 2018

#### Rating

Facilities	Amount (Rs. crore)	Rating <sup>1</sup>	Rating Action  Revised from  CARE A3 (A Three)	
Short term Bank Facilities	50.00	CARE A4+ (A Four Plus)		
Total Facilities	50.00 (Rs. Fifty crore only)			

Details of facilities in Annexure-1

### **Detailed Rationale and Key Rating Drivers**

The revision in rating assigned to the bank facilities of Wockhardt Hospitals Ltd (WHL) reflects weakening in the credit profile of its one of the promoter group company i.e. Carol Info Services Limited (CSIL) which extends support to WHL as and when required. Apart from CSIL there are other promoter group companies which do provide support to WHL. Furthermore, WHL is dependent on fund infusion by the promoters/promoter group entities like CSIL to take care of its operational cum capex needs and loan obligations as it continued to post cash losses in FY18 (refers to period between April 01 to March 31). In FY19 till September 30, 2018; WHL has received Rs.35 crore from CSIL demonstrating support from the promoters. Performance of CSIL is driven by credit profile of the flagship company of the group i.e. Wockhardt Ltd (WL, rated CARE BBB-; Negative/CARE A3) who is a key tenant accounting for 95% of CISL's revenues and 91% of its leased space during FY18 (refers to period between April 01 to March 31).

The rating continue derive strength from the experience of the promoters and track record of the company in managing chain of single/multi-specialty hospitals coupled with large variety of healthcare services along with favorable locations and continuous support from the promoters/group entities by way of infusion of funds. Furthermore, WL and WHL, both, share a common name "Wockhardt" which represent the group's presence in the pharmaceutical business.

Nonetheless, the rating strength is tempered by subdued operational performance since FY15 leading into continued losses. The rating is further constrained by the capital intensive and competitive nature of healthcare industry along with challenges pertaining to attracting and retaining quality doctors and medical professionals.

Any further weakening in credit profile of promoter/promoter group entities or reduction in likelihood of timely infusion of funds/support from them or deterioration in operating performance of WHL remains key rating sensitivity.

## Detailed Rationale & Key Rating Drivers Key Rating Strengths

Well established promoter group with expected continuation of support: Wockhardt group belongs to Dr Habil F Khorakiwala led Khorakiwala family which has an established track record of over five decades in pharmaceutical sector with global presence across various therapeutic segments. The group is looked after by Mr Habil F Khorakiwala (Chairman), along with his daughter Ms Zahabiya Khorakiwala (Managing Director) and sons Dr Murtaza Khorakiwala and Dr Huzaifa Khorakiwala. The board is supported by professionals with experience in their respective fields.

Over the past few years (FY13 till FY17), the promoters have infused Rs.461 crore till FY18 (Rs.32 crores in FY18, Rs.53 crore in FY17 and Rs.80 crore in FY16) in the company. In FY19 till September 30, 2018; WHL has received Rs.35 crore from CSIL demonstrating support from the promoters. CSIL's rating is driven by credit profile of its key tenant, i.e. WockhardtLimited (rated CARE BBB-; Negative/A3) which accounts for 91% of CISL's leased space and 95% of its revenue.

**Established operations as a single/multi-specialty hospital:** Established in 1991, WHL's operations are well established as it manages a chain of 8 hospitals offering a range of medical and surgical care in almost all major therapeutic segments with specialist doctors available round the clock.

Strong presence in Western India albeit stabilisation risk associated with its recently commissioned hospitals: WHL manages a chain of nine hospitals under the name of 'Wockhardt Hospitals' located across Western India, i.e. six (6) in Maharashtra viz. Mumbai (3), Nagpur (2) and Nashik (1); followed by two (2) in Gujarat viz. one each in Rajkot and Surat and one (1) in Goa. The two major hospitals located at Mumbai Central (350 beds) and Mumbai Suburban-Mira Road (330 beds), which commissioned operations in FY15, have state of the art facilities and are in gestation period. These 2 hospitals contributed around 40% to sales in FY18.

Flat growth in revenues with low occupancy levels resulting into continued operational losses: WHL's total operating income exhibited compounded annual growth rate (CAGR) of around 8.7% over the past three years (FY16 to FY18). However, the company continued to incur cash losses from FY15 onwards owing to lower occupancy rates albeit improving on a y-o-y basis and commercialisation of two major hospitals in FY15 resulting into higher costs. Since then on

## **Press Release**



the back of lower occupancy levels across its several hospitals coupled with stabilization risk and gestation period associated with its two major hospitals resulted into continued losses.

**Moderate capital structure albeit weak debt coverage ratios:** Capital structure continues to be moderate and marginally improved to 0.73x as on March 31, 2018 vis-à-vis 0.87x as on March 31, 2017. Debt coverage ratios continued to be weak on account of cash losses.

#### Liquidity

Liquidity support is derived being part of Wockhardt group as WHL gets continuous support from promoters/group entities. As on September 30, 2018 WHL has received Rs.34.96 crore from promoters/group entities. WHL continues to make cash losses and it is completely dependent on fund infusion by the promoters/group entities to take care of its interest servicing and term loan repayments.

#### **Key Rating Weaknesses**

**Capital intensive nature of industry:** The hospital industry is a capital intensive industry with a long gestation period. Generally, payback period for a new hospital is in the range of 5-6 years due to lower occupancy rate in the initial phase of operations. Further, the maintenance capex required for the hospital industry also remains high.

Intensely competitive industry: The healthcare industry is highly competitive with a large number of established organized players and their growing network of hospitals. The competition is expected to intensify with the expected entry of public private partnerships in this segment. However, WHL has empanelled quality doctors and set up state of the art facilities to combat competition.

**Industry Outlook:** Indian healthcare sector is recognised as one of the fastest growing industries, and is expected to reach US\$ 280 billion by 2020. Rising income level, greater health awareness, increased precedence of lifestyle diseases and improved access to insurance would be the key contributors to growth. The sector is expected to generate 40 million jobs in India by 2030.100,000 jobs are expected to be created from Ayushman Bharat, the National Health Protection Scheme. As of October 16, 2018, number of Primary Health Centres (PHCs) increased to 33,047and number of sub-centres reached 167,880. The hospital industry is expected to reach Rs. 8.6 trillion (US\$ 132.84 billion) by FY22.

## Analytical approach:

For arriving at the ratings, CARE has considered audited standalone financial statements of Wockhardt Hos pitals for FY18. Furthermore, operational synergies and financial linkages/support from the promoters/promoter group entities have been considered.

## **Applicable Criteria**

CARE'S Policy on Default Recognition
Criteria for Short Term Instruments
Rating Methodology: Factoring Linkages in Ratings
Financial ratios – Non-Financial Sector

## **About the Company**

Incorporated in 1991, Wockhardt Hospitals Limited (WHL), formerly known as First Hospitals & Heart Institute Limited, is promoted by Dr Habil Khorakiwala, Chairman, Wockhardt Group. WHL is a part of Wockhardt group of companies which has an established presence in the pharmaceutical sector through its flagship company i.e. Wockhardt Limited (WL, rated 'CARE BBB-; Negative/CARE A3') which is engaged in manufacturing and marketing of pharmaceuticals, bio-pharmaceutical formulations, and active pharmaceutical ingredients (APIs) and Vaccines.

As on March 31, 2018, WHL is a subsidiary of Dartmour Holdings Private Limited (DHPL) which holds 72.34% equity stake in the company. Carol Info Services Limited (CISL) holds 13.58% while Mr H F Khorakiwala holds 8.03%.

WHL provides single-specialty and multi-specialty tertiary health care services through its managed chain of nine operational hospitals with a total capacity of 1,232 beds as on March 31, 2018 (1,232 beds as on March 31, 2017). All the hospitals are run, operated and managed by WHL under the brand name "Wockhardt". WHL has more than a decade old relationship with Partners Harvard Medical International (PHMI) which is involved in clinical training and organizational development. Besides, many of the hospitals managed and run by the company are having accreditation of the NABH (National Accreditation Board of Hospitals & Healthcare).

## **Press Release**



#### **Brief Financials:**

Brief Financials (Rs. crore)	FY17 (A)	FY18 (A)
Total operating income	451.75	467.22
PBILDT	-18.98	-5.93
PAT	-78.12	-80.49
Overall gearing (times)	0.87	0.73
Interest coverage (times)	-0.39	-0.11

Status of non-cooperation with previous CRA: Not Applicable

Any Other information: Not Applicable

Rating History (Last three years): Please refer Annexure-2

**Note on complexity levels of the rated instrument:** CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.

#### **Analyst Contact**

Name: Mr. Murtuza Patrawala

Tel: +91-22-6754 3456

Email: murtuza.patrawala@careratings.com

## **About CARE Ratings:**

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

## Disclaimer

CARE's ratings are opinions on credit quality and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments.

In case of partnership/proprietary concerns, the rating/outlook assigned by CARE is based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors.

<sup>\*\*</sup>For detailed Rationale Report and subscription information, please contact us at www.careratings.com



# Annexure-1: Details of Instruments/Facilities

Name of the Instrument	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue	Rating assigned along with Rating
				(Rs. crore)	Outlook
Non-fund-based - ST-	-	-	-	50.00	CARE A4+
Bank Guarantees					

# Annexure-2: Rating History of last three years

Sr.	Name of the	Current Ratings		Rating history				
No.	Instrument/Bank Facilities	Туре	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in	Date(s) & Rating(s) assigned in	Date(s) & Rating(s) assigned in	Date(s) & Rating(s) assigned in
					2018-2019	2017-2018	2016-2017	2015-2016
1.	Non-fund-based - ST-	ST	50.00	CARE	-	1)CARE A3	1)CARE A3	-
	Bank Guarantees			A4+		(05-Mar-18)	(03-May-16)	
						2)CARE A3		
						(18-Apr-17)		



## CONTACT

## **Head Office Mumbai**

Ms. Meenal Sikchi Cell: + 91 98190 09839

E-mail: meenal.sikchi@careratings.com

Ms. Rashmi Narvankar Cell: + 91 99675 70636

E-mail: rashmi.narvankar@careratings.com

Mr. Ankur Sachdeva

Cell: +919819698985

E-mail: ankur.sachdeva@careratings.com

Mr. Saikat Roy

Cell: +919820998779

E-mail: saikat.roy@careratings.com

## **CARE Ratings Limited**

(Formerly known as Credit Analysis & Research Ltd.)

Corporate Office: 4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Tel: +91-22-6754 3456 | Fax: +91-22-6754 3457 | E-mail: care@careratings.com

#### **AHMEDABAD**

#### Mr. Deepak Prajapati

32, Titanium, Prahaladnagar Corporate Road,

Satellite, Ahmedabad - 380 015

Cell: +91-9099028864 Tel: +91-79-4026 5656

E-mail: deepak.prajapati@careratings.com

## **BENGALURU**

#### Mr. V Pradeep Kumar

Unit No. 1101-1102, 11th Floor, Prestige Meridian II,

No. 30, M.G. Road, Bangalore - 560 001.

Cell: +91 98407 54521

Tel:+91-80-4115 0445, 4165 4529

Email: <a href="mailto:pradeep.kumar@careratings.com">pradeep.kumar@careratings.com</a>

#### **CHANDIGARH**

## Mr. Anand Jha

SCF No. 54-55,

First Floor, Phase 11,

Sector 65, Mohali - 160062

Chandigarh

Cell: +91 85111-53511/99251-42264

Tel:+91-0172-490-4000/01

Email: anand.jha@careratings.com

## **CHENNAI**

## Mr. V Pradeep Kumar

Unit No. O-509/C, Spencer Plaza, 5th Floor,

No. 769, Anna Salai, Chennai - 600 002.

Cell: +91 98407 54521

Tel: +91-44-2849 7812 / 0811

Email: <a href="mailto:pradeep.kumar@careratings.com">pradeep.kumar@careratings.com</a>

### COIMBATORE

# Mr. V Pradeep Kumar

T-3, 3rd Floor, Manchester Square

Puliakulam Road, Coimbatore - 641 037.

Tel: +91-422-4332399 / 4502399

Email: <a href="mailto:pradeep.kumar@careratings.com">pradeep.kumar@careratings.com</a>

#### **HYDERABAD**

## Mr. Ramesh Bob

401, Ashoka Scintilla, 3-6-502, Himayat Nagar,

Hydera bad - 500 029. Cell: +91 90520 00521 Tel: +91-40-4010 2030

E-mail: ramesh.bob@care ratings.com

#### JAIPUR

#### Mr. Nikhil Soni

304, Pashupati Akshat Heights, Plot No. D-91, Madho Singh Road, Near Collectorate Circle,

Bani Park, Jaipur - 302 016. Cell: +91 – 95490 33222 Tel: +91-141-402 0213 / 14

E-mail: nikhil.soni@careratings.com

#### **KOLKATA**

## Ms. Priti Agarwal

3rd Floor, Prasad Chambers, (Shagun Mall Bldg.) 10A, Shakespeare Sarani, Kolkata - 700 071.

Cell: +91-98319 67110 Tel: +91-33-4018 1600

E-mail: priti.agarwal@care ratings.com

# **NEW DELHI**

## Ms. Swati Agrawal

13th Floor, E-1 Block, Videocon Tower, Jhandewalan Extension, New Delhi - 110 055.

Cell: +91-98117 45677 Tel: +91-11-4533 3200

E-mail: <a href="mailto:swati.agrawal@careratings.com">swati.agrawal@careratings.com</a>

#### **PUNE**

## Mr.Pratim Banerjee

9th Floor, Pride Kumar Senate,

Plot No. 970, Bhamburda, Senapati Bapat Road,

Shivaji Nagar, Pune - 411 015. Cell: +91-98361 07331

Tel: +91-20-4000 9000

E-mail: pratim.banerjee@careratings.com

CIN - L67190MH1993PLC071691